Arkis BioSciences, a young medical technology company out of Knoxville, Tennessee, won FDA clearance for its CerebroFlo external ventricular drainage catheter. 
The device indicated for positioning within the ventricular cavity of the brain and establishing a drainage channel to release cerebrospinal fluid.
The company touts the use of Endexo, a coating material from Interface Biologics (Toronto, Canada), on the surface of the new catheter. It stops platelet activation and reduces coagulation activity in its vicinity, helping to prevent infections, occlusions, and other potential problems, which the firm says is backed up by clinical studies in other catheters using Endexo.
“Arkis’ in vitro studies have shown 99% less biomatter accumulation onto CerebroFlo’s catheter surfaces, which may reduce fouling,” said Seaver. “Further in vitro studies are underway to characterize CerebroFlo’s ability to prevent infectious biofilm formations without the use of eluting antibiotic drugs.”
Product page: CerebroFlo EVD Catheter…
Via: Arkis…
